Oncogenic potential
Several of these themes are highlighted by articles appearing in the current issue of the JCI, in which two groups, using related approaches, focused on members of the family with sequence similarity, members A and B (FAM83A and FAM83B) (7, 8) . Although differences between these reports clearly exist, the findings and conclusions of these groups exhibit marked similarities and suggest that these genes may contribute both to the pathophysiology of breast cancer as well as to resistance to EGFR inhibitors. In the study by Lee et al., from the laboratory of Mina J. Bissell, the authors used a threedimensional phenotypic reversion assay in breast cancer cells to identify FAM83A as a candidate oncogene capable of conferring EGFR inhibitor resistance (7). This group observed that forced FAM83A expression enhanced breast cancer cell proliferation and invasiveness, while at the same time increasing resistance to TKIs. Conversely, depletion of FAM83A reverted the malignant phenotype, reduced tumor growth in immunocompromised mice, and increased TKI responsiveness. Interestingly, expression of FAM83A was associated with increased phosphorylation of members of the RAS/ RAF/MEK/ERK and PI3K/AKT/mTOR pathways. These findings, along with evidence that FAM83A expression correlates inversely with prognosis of patients with breast cancer, raise the possibility that this gene may contribute both to breast cancer aggressiveness as well as TKI resistance. Significantly, FAM83A was observed to interact with c-RAF and PI3K p85 (7), components of EGFR downstream survival pathways, which, as noted previously, have both been implicated in EGFR inhibitor resistance.
In the study by Cipriano et al., from the laboratory of Mark W. Jackson, the authors used a validation-based insertional mutagenesis screen and identified a related gene, FAM83B, capable of transforming human in the PI3K/AKT/mTOR or RAS/RAF/ MEK/ERK pathways (4) . Adding further to the complexity are the observations that mutations in pathway components (e.g., activating EGFR mutation in lung cancer, ref. 5 , and B-RAF mutation in melanoma) may render those tumors exquisitely sensitive to inhibitors of those kinases (6) .
resistance of cells to tyrosine kinase inhibitors (TKIs) may reflect not only mutations that prevent drug binding (3), but also cross-talk between and compensatory activation of downstream pathways that relieve the cell of its addicted phenotype. In the case of EGFR inhibitors, the latter phenomenon often involves perturbations Hypothetical model by which candidate oncogenes such as FAM83A and FAM83B may influence transformed cell behavior, while simultaneously modifying responses to TKIs. Tyrosine kinases such as EGF are frequently dysregulated in cancer and signal downstream to multiple growth and survival pathways, including the RAS/RAF/MEK/ERK and the PI3K/AKT pathways. The prosurvival actions of these pathways are mediated, at least in part, through phosphorylation of proapoptotic and antiapoptotic BCL-2 family proteins (e.g., BIM, BAD, and MCL-1), leading to alterations in the relative abundance of as well as interactions between these proteins. Note that AKT acts indirectly to spare MCL-1 by inhibiting glycogen synthase kinase-mediated (GSK-mediated) MCL-1 phosphorylation and degradation. TKIs act by blocking EGF signaling to these key pathways, and modification of the balance between BCL-2 family proteins may contribute to TKI-mediated lethality. As shown by the dashed arrows, FAM83A and FAM83B could theoretically act downstream of EGF but upstream of BRAF and p85-PI3K to promote activation of these survival pathways, leading to attenuation of cell death. FAM83A and FAM83B may also, through a yet to be defined mechanism, modify the extent or tonicity of EGF signaling itself. By acting at sites downstream of EGF, FAM83A and FAM83B may thereby bypass the block to EFG survival signaling induced by TKIs, effectively relieving the cell of its addiction to this survival pathway. Such a phenomenon could theoretically be prevented by either developing inhibitors of FAM83A and/or FAM83B that interfere with their interactions with proteins such as BRAF or specifically targeting downstream components of the pathways responsible for the prosurvival actions of these proteins. Adapted with permission from Nature Reviews Cancer (17) . and FAM83B, or the proteins that they encode, could represent candidate targets suitable for therapeutic intervention. Clearly, the ultimate success of such an approach will depend upon better understanding of the functions of these proteins, which, based upon preliminary findings, appear to be quite pleiotropic in nature. In this regard, evidence is presented suggesting that the activation of CRAF, and resulting transformation, involves FAM83B binding (8) . While such protein-protein interactions are no longer considered "undruggable," successful development of such inhibitors will hardly be a trivial enterprise. Even if this approach is not feasible, an increased understanding of the downstream targets responsible for FAM83A-or FAM83B-mediated TKI resistance will highlight complementary therapeutic targets that might specifically enhance TKI activity in patients with tumors exhibiting dysregulated FAM83A or FAM83B. As labor intensive as this approach may be, the current limitations of TKIs in the treatment of breast cancer and other tumor types justifies such efforts.
has been related to constitutive or stimulated activation of AKT or MEK/ERK (10, 11) . Thus, FAM83A and FAM83B may function by bypassing RTK dependence through activation of ERK1/2, AKT, and possibly other kinases, effectively relieving the cell of its addiction to EGFR. On the other hand, the observation that FAM83B may prolong EGFR signaling raises the possibility that this gene may act at a more proximal point in the network to reduce TKI lethality. To answer these questions definitively, a more systematic functional analysis of FAM83A-and FAM83B-mediated perturbations in these signaling networks in the presence of TKIs will be required.
Another issue to be addressed is identification of the mechanism(s) by which FAM83A-and FAM83B-induced activation of MAPK and other signaling pathways promotes transformed cell survival, particularly in the presence of TKIs. It is generally thought that the prosurvival effects of MAPK and AKT are integrated at the level of BCL-2 family proteins, including BIM and BAD (4) . In this context, it has been shown that TKI responsiveness can be highly dependent upon expression of the proapoptotic BH3-only protein BIM, and a very recent study identified a common BIM deletion polymorphism as a mediator of intrinsic resistance to TKIs (12) . Significantly, AKT-and ERK-mediated BIM phosphorylation leads to its ubiquitination and proteasomal degradation (13, 14) . It would therefore be very interesting to determine what effect, if any, expression of FAM83A or FAM83B might have on BIM abundance, and whether such actions might contribute to TKI resistance. In addition, it is recognized that, aside from the total and relative levels of proapoptotic to antiapoptotic BCL-2 family members, cell survival may also be determined by physical interactions between these proteins. In this context, ERK phosphorylation of BIM diminishes its proapoptotic association with BAX (15) . Consequently, FAM83A-and FAM83B-mediated activation of the CRAF-MAPK axis may diminish TKI responsiveness by altering Bim interactions with antiapoptotic proteins such as MCL-1 (16) . A summary of the hypothetical basis by which FAM83A and FAM83B might influence the response of tumor cells to TKIs is illustrated in Figure 1 .
The starting point for translation
Finally, the studies by Lee et al. and Cipriano et al. raise the possibility that FAM83A mammary epithelial cells (8) . As observed in the case of FAM83A, silencing FAM83B diminished the growth of these cells, while forced expression reduced their sensitivity to TKIs. In addition, the consequences of FAM83B expression were related to interactions with CRAF, accompanied by activation of ERK1/2 as well as AKT, pathways previously implicated in circumvention of TKI-mediated lethality. Finally, FAM83B expression resulted in more sustained EGFR phosphorylation (8), a phenomenon that might plausibly contribute to TKI resistance. Together, these companion studies identify two related candidate oncogenes that might both contribute to EGFR resistance, possibly through physical or other interactions with CRAF and potentially other common downstream cytoprotective pathways. If validated, this information could help to identify new targets for therapeutic interventions in breast cancer and possibly other cancers and may also assist in the development of strategies designed to overcome resistance to currently available TKIs.
Drivers or passengers?
Although the results of and conclusions drawn from these studies appear logical and consistent, a number of questions remain to be addressed. For one thing, while dysregulation of FAM83A and FAM83B appears to occur relatively frequently in human tumor specimens, it is uncertain whether they are primarily responsible for transformation in this setting or instead represent passenger mutations that play more of a permissive role. The increased expression of these genes in diverse tumor types complicates the task of defining their precise etiological role in tumorigenesis. Consequently, considerable work will be required to define the role of FAM83A and FAM83B in carcinogenesis more definitely.
One of the more interesting features of the two studies is that they focus attention on the interdependent phenomena of oncogene addiction and drug resistance. More specifically, both studies shine a spotlight on the role of RTK downstream pathways, particularly the RAS/RAF/MEK/ERK and PI3K/AKT cascades, in both the transforming activities of FAM83A and FAM83B as well as escape from the lethal effects of TKIs. It has long been recognized that aberrant EGFR signaling exerts its prosurvival effects, at least in part, through activation of these pathways (9) . Moreover, resistance to TKIs 
The problem
The underlying pathologic processes driving the symptoms of neurodegenerative disease cannot be followed in living subjects without better biomarkers. The difficulty in identifying such biomarkers of disease progression has impeded the development of therapeutic strategies to combat it. The study by Fanara et al. on cerebrospinal fluid (CSF) kinetic biomarkers of axonal transport in this issue of the JCI marks an important contribution to the field of measuring difficult-to-assess brain processes in vivo (1) . The authors' work expands on a series of earlier studies in murine models that used heavy water ( 2 H 2 O) labeling to investigate microtubule dynamics and stabilization by taxanes with neuroprotective potential (2, 3). Here, Fanara et al. systematically developed a biomarker of microtubule function (1), and their work has implications for the more general problem of developing biomarkers for any brain process.
Ideally, in the development of biomarkers intended for human application, one needs a model system in which variables can be controlled and manipulated. Although genetic or lesion models of human disease are available, to be clinically relevant, the direct measures possible in animal brain coupled to a biomarker analysis must be translatable to humans. CSF is an attractive sample source. Although technical issues involved in sampling from mice have discouraged many groups, Fanara et al. provide a compelling case that it is possible to relate a pathologic process in a murine model to a specific CSF analyte measurable in mice and humans.
CSF as a biomarker source
To appreciate the potential importance of a wider application of this strategy of biomarker development, we must consider what traditional human CSF studies have and have not been able to deliver in the past. Human CSF has been a source of biomarkers, especially as an index of drug action, for decades. For instance, antidepressants were shown to produce hypothesized effects on CSF amine neurotransmitter metabolites in the early 1970s (4). The kinetic principles for interpreting concentrations of analytes in CSF were established during this same period, including the use of stable isotopes (5) . Recently, especially in Alzheimer's disease (AD), discovery proteomic assays have identified a number of analytes beyond amyloid-β and phospho-tau, increasing interest in CSF as a source of biomarkers of disease (6) . Even when robust relationships can be established between a CSF analyte and a disease process or drug action, gaps remain in our knowledge regarding how best to interpret a concentration change. Definitive interpretations require more precise knowledge of the sites of formation of the analyte as well as the processes that control its concentration in CSF. Figure 1 provides a minimal model of the processes that would need to be quantitatively understood in order to fully interpret behavior of any CSF analyte. Even with simplifying assumptions, such as common rate constants for molecule formation and movement from all brain tissues into the CSF, other rate constants are relevant to our understanding; these include not only direct egress into peripheral compart-
